Featured Research

from universities, journals, and other organizations

New class of platelet blockers proves effective in phase III trial, study suggests

Date:
March 26, 2012
Source:
American College of Cardiology
Summary:
Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of the arteries, according to new research.

Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of the arteries, according to research presented March 26 at the American College of Cardiology's 61st Annual Scientific Session. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field.

Each year, more than a million Americans suffer a heart attack. For those who survive, doctors routinely prescribe aspirin therapy to help prevent blood clot formation in the arteries that can lead to another heart attack. Other platelet blockers, such as clopidogrel, are often added for as long as a year but it is unclear whether adding any platelet blocker to aspirin beyond this timeframe is useful. Despite such therapies, survivors of heart attack have an almost 15 percent chance of having another atherosclerosis-related event that brings them to the hospital within a year.

Now, researchers led by the TIMI Study Group at Brigham & Women's Hospital in Boston, Mass. have shown, for the first time, that adding a new antiplatelet agent on top of standard therapy, including aspirin, is effective for long-term secondary prevention in stable patients with a prior heart attack. When used with aspirin and other standard antiplatelet therapy in a broad group of patients with previous heart attack, stroke or peripheral arterial disease, vorapaxar reduced the risk of cardiovascular death, heart attack or stroke by an additional 13 percent (9.3 vs. 10.5 percent at three years, p<0.001). This reduction in new cardiovascular events appeared greatest in patients with prior heart attack, among whom there was a 20 percent decline in these events (p<0.001).

Vorapaxar is the first of a new class of investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonists. Unlike other antithrombotic drugs, vorapaxar blocks thrombin from stimulating platelets to stick together and create clots. Blood thinners, like coumadin, and other antiplatelets like aspirin or clopidogrel, do not directly target these same actions of thrombin.

"In the lab, we have seen very compelling science showing the importance of thrombin's action on platelets causing blood clots in arteries," said David A. Morrow, MD, MPH, senior investigator at the TIMI Study Group, director of the Samuel A. Levine Cardiac Unit at Brigham & Women's Hospital, and the study's lead investigator. "This is the first study to show definitively that blocking this pathway reduces the risk of suffering another cardiovascular event."

This randomized, double blind, placebo-controlled, multinational study followed 26,449 patients for more than two years while receiving standard antiplatelet therapy for established atherosclerosis, including previous heart attack (n=17,779), stroke (n=4,883), or atherosclerotic narrowing in the arteries of the legs (n=3,787). Participants were randomly assigned to either take the investigational platelet blocker (2.5 mg orally once daily) with standard therapy, or a placebo with standard therapy.

"It's exciting to find clearly that we can reduce the risk of a recurrent thrombotic event by adding another platelet inhibitor to aspirin over the long-term," Dr. Morrow said. "Adding this new class of antiplatelet therapy reduced the risk of new cardiac events in stable patients, especially among the subset of patients with a prior heart attack."

Dr. Morrow commented that if vorapaxar becomes available for clinical use, it does not appear suitable for everyone with atherosclerosis. "Of the groups we studied, the benefit was compelling to us only in patients with a prior heart attack," said Dr. Morrow. In addition, this new therapy was found to increase the risk of severe bleeding, including intracranial bleeding. The risk of intracranial bleeding was highest among patients who have suffered from previous strokes; vorapaxar would likely not be appropriate for stroke victims or patients at high risk of bleeding. Stroke patients who were enrolled in the study ended their participation early after advice by the study's data and safety monitoring board.

Patients who took vorapaxar had significantly more bleeding events (GUSTO moderate or severe bleeding at three years 4.2 percent with vorapaxar vs. 2.5 percent with placebo, p<0.001). Intracranial hemorrhage was higher with vorapaxar than placebo (1.0 vs. 0.5 percent, p<0.001) with lower overall rates in patients with no history of stroke (3 years: 0.6 percent with vorapaxar vs. 0.4 percent with placebo, p=0.049).

Dr. Morrow and his team look forward to learning more from this very rich dataset to identify the patients who may have the best balance of benefit vs. bleeding risk with this agent.

The study was funded by Merck Research Laboratories. Dr. Morrow has received research grant support and consulting fees from Merck and other manufacturers of antiplatelet and anticoagulant therapies.

This study will be simultaneously published in New England Journal of Medicine and will be released online at the time of presentation.


Story Source:

The above story is based on materials provided by American College of Cardiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. David A. Morrow, Eugene Braunwald, Marc P. Bonaca, Sebastian F. Ameriso, Anthony J. Dalby, Mary Polly Fish, Keith A.A. Fox, Leslie J. Lipka, Xuan Liu, José Carlos Nicolau, A.J. Oude Ophuis, Ernesto Paolasso, Benjamin M. Scirica, Jindrich Spinar, Pierre Theroux, Stephen D. Wiviott, John Strony, Sabina A. Murphy. Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine, 2012; 120324060009004 DOI: 10.1056/NEJMoa1200933

Cite This Page:

American College of Cardiology. "New class of platelet blockers proves effective in phase III trial, study suggests." ScienceDaily. ScienceDaily, 26 March 2012. <www.sciencedaily.com/releases/2012/03/120326113815.htm>.
American College of Cardiology. (2012, March 26). New class of platelet blockers proves effective in phase III trial, study suggests. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2012/03/120326113815.htm
American College of Cardiology. "New class of platelet blockers proves effective in phase III trial, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/03/120326113815.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) — Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) — New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) — A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) — Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins